From a broad societal perspective, the economic burden of Parkinson's disease ranges from direct medication expenses to costs associated with home help and lost production. The last two generally arise in the more advanced stages of the disease. Savings are nevertheless possible and the two main ways of attaining this are by slowing down disease progression and reducing the time patients spend in off-periods. Earlier onset of optimised treatment, both in the initial and later disease stages, has the potential to achieve both.
Like other chronic neurodegenerative diseases, Parkinson's disease (PD) is associated with an impaired quality of life (QoL) for patients and costs to society. In Sweden at 2011 prices, the overall average cost per patient and year has been estimated at SEK (Swedish crowns) 148,000 or €16,500. 1 In 2005 in Europe, the direct cost was estimated as €10.7 billion per year, but it was considered that the total costs may be around 40 % more. 2 Significantly, future costs in developed countries were predicted to double by 2030.
Most of the costs associated with PD fall outside of the healthcare system, e.g. they are due to home care or lost productivity. A growing body of expertise believes that allocating more resources to early, optimised therapy can offset direct medication costs by raising patient QoL. This should reduce their need for home care and prolong the time they spend at work. We provide support for this view and show how economic simulation modelling can help generate meaningful cost-utility data.
Socioeconomic Experiences of Focused Treatment in Haemophilia
In developing countries with a per capita gross national product (GNP) of less than US$2,000, few citizens with haemophilia live beyond the age of nineteen. Many do not survive childhood. However, survival to adulthood and beyond increases approximately fivefold if these people have access to a specific haemophilia treatment centre (HTC).
Data collected by the World Federation of Haemophilia (WFH) 3 clearly
show that even minimal level treatment at a HTC boosted recovery from bleeding episodes and increased survival to adulthood. This resulted in a quicker return to school or work, as well as preserved functional independence. Absenteeism decreased, productivity improved and the burden on caregivers was reduced.
A relatively modest investment in the health of haemophilia sufferers thus benefits both government and society since as adults they are able to work and contribute to the community. The long-term financial consequences of higher morbidity are avoided.
This simple yet dramatic example has parallels with the treatment of PD in western countries. Although the costs of treating PD may be higher than the expenses of running a basic HTC, the economic resources of industrialised nations are correspondingly greater. So just as it makes economic sense for countries with even limited resources to provide organised haemophilia care, developed countries should evaluate the cost benefits of the therapeutic options available for PD. Expenses associated with providing optimised treatment as early as possible could be more than offset by improved outcome.
Symptoms of Parkinson's Disease
PD is still primarily regarded as a movement disorder caused by the depleted production of the neurotransmitter substance dopamine (DA). 4 It is characterised by motor symptoms (MS) such as slowness of movement, rigidity, tremors and balance problems. 5 This focus on MS has largely dictated the development of therapeutic options for treating PD and the administration of levodopa (the precursor of DA) and/or dopamine agonists has met with much success in combating the major visible motor complications of PD, especially when given orally.
Recent years have also seen an increased awareness of non-motor symptoms (NMS) as a cause of concern for PD patients. 6 Many NMS are considered to be as troublesome as MS or even more so. Typical NMS include depression, stress incontinence, sleep disorders, concentration difficulties, impaired memory, apathy and daytime sleepiness.
Current Treatment Approaches to Parkinson's Disease -The Potential of Early Treatment
The treatment of PD continues to make good progress and several recent advances now complement more traditional therapies. Similar problems are likely to arise at home. Patients will find it increasingly difficult to participate in family activities. Their need for active help will become greater and they may eventually be regarded as a burden for a well-functioning family life. 9 The QoL for all involved seems certain to suffer. Having to engage an outside care-giver or pay for a place in a nursing home may be an option that the family is forced to consider. All in all, advanced PD is a significant burden for society to bear.
Therapeutic Alternatives for Advanced-stage Disease
As noted above, optimising tablet treatment and/or adding MAO-B-inhibitors, dopamine agonists or COMT-inhibitors may provide some temporary respite, as would use of a transdermal patch such as Neupro ® , which contains the dopamine agonist rotigotine. It has also been shown that DBS has an excellent effect on MS for up to 10 years in advanced PD. 12 Dyskinesias and motor fluctuations were greatly reduced and most patients required only half the amount of conventional medication. Compared with best medical treatment (BMT), DBS improved patient QoL. Moreover, results from several studies show that even NMS benefit from such advanced treatments. 13 When combined with specific therapies for NMS, e.g., anti-depressants or urological therapy, the overall result can be a significant improvement in patient QoL and capability for productive work.
Timely Application of New Therapies Requires Simpler Assessment Methods
Today, advanced therapies are generally first considered when the motor fluctuations have become so severe as to exclude the patient from enjoying a normal family and working life. Additionally, the evaluation process requires a spectrum of experts with considerable experience of PD plus specialist treatment centres. As well as taking time, this means that many patients with advanced PD never get the chance to be considered for these therapies. 14 Some may not even know about them. One probable outcome is that many PD patients may never receive optimal medication, which can mean that they are forced to give up work and/or move into care much earlier than is otherwise necessary.
As new effective treatments for PD are evolving all the time, 7 it is important that patients seek medical advice as soon as the early signs of PD are detected. Investing in an earlier and simpler means of evaluating their need for newer therapies could thus repay itself in reduced indirect costs for society as well as greater QoL for patients.
Calculating the Economic Cost of Parkinson's Disease on Society
Stabilising patients' medical condition with early, optimised treatment should help them avoid the disruptive effect of the symptoms on their working situation and family life. There could thus be socioeconomic gains to be won by slowing down PD progression at earlier stages than is often the practice today. Furthermore, in an ageing population with increased disease prevalence, the gains for society, patients and care-givers could be considerable. The mean total annual cost for PD thus approximated to SEK 124,000
(approximately US$12,400; €13,800) per patient per year at 2000 prices (see Figure 1) .
Significantly, the cost per patient increased according to the Hoehn and Yahr (H&Y) stage of disease. In H&Y stage I, the cost was SEK 55,000
(US$5,500, €6,100). By stage V this had risen to SEK 181,000 (US$18,100, €20,100) (see Figure 2 ).
At each H&Y stage, the indirect cost of lost production was the greatest single item, accounting for 42 % of the mean annual cost. In the most severe stage, the costs for home care are extensive.
A Finnish study on the economic burden and impaired health-related QoL (HRQoL) made at about the same time as the Swedish study also noted a strong relationship between the severity of PD, decreasing HRQoL and increasing costs. 16 
International Comparisons Show Costs per Country Vary
That PD places a financial burden on society, both in direct and indirect costs, has also been noted in other countries, although differences in healthcare organisation, reimbursement policies, etc., make firm cross-national comparisons somewhat uncertain.
When the Swedish study compared its direct healthcare costs with those found in German, French, British and North American investigations, it found that the highest medication costs occurred in Germany. In that country, drugs accounted for 42 % of the total healthcare costs, approximately twice that found in France and the US (see Figure 3) . In the US, indirect costs and costs for informal care were substantial.
Total annual direct healthcare costs in Sweden appeared to be lower than the other four countries. Swedish home-care costs were higher than direct healthcare costs and also higher than that estimated Analysing costs by H&Y stage revealed that the costs of retirement and healthcare insurance payments increase disproportionately in the advanced disease stages. One conclusion drawn by the review authors was that due to the expensive nature of the disorder, the medical community should ensure that enough funding is available for suitable and innovative treatments.
The significance of lost employment on the cost to society of PD, especially in its advanced stages, was indicated by UK studies made at about the same time as the German review. 18 In groups of 151 and 308
PD patients with onset age before 65 years, 52 and 57 % of patients retired early due to PD, while 18 and 5 % of patients were unemployed and 8 and 11 % part-time-employed. Mean age of retirement was 55.8 years compared to an average retirement age of 62 years in the UK population. Forty-six per cent had stopped working after a disease duration of five years and 82 % after 10 years. It was concluded that on average, PD leads to loss of employment in less than 10 years of onset.
Allocating Healthcare Priorities
To provide information and support discussions about future cost allocations and healthcare priorities, an attempt was made to estimate the drug and treatment costs for PD patients during 2009 in Stockholm
County as well as in the whole of Sweden. prices. The annual total cost per patient would thus be SEK 139,000.
Like others before them, the authors observed that the impact of PD places a significant burden on patients and society.
Health Economic Analyses for Advanced Treatments
Health economic analyses will be important when estimating the costs of modern PD treatments and whether these costs are reasonable in relation to the benefits that they bring and what society is prepared to pay for them. Willis and Gradl, 2010. 19 to only 0.02 of this increase (conservatively estimated 
Conclusions
New therapeutic developments as well as advanced treatments such as CDS via pumps and DBS have a true potential to improve the QoL of PD patients, both in early and advanced disease stages.
Providing optimised treatment at the right time should therefore give significant cost benefits. The most obvious will be that patients stay longer in their normal housing, enjoy a good social life and remain longer at their place of work. This greater independence should lower the economic cost burden on society.
Although many of the advanced therapies may seem expensive, the investment they represent will reduce the indirect costs of PD in the long-term. One prerequisite for beginning optimised treatment earlier is the availability of simpler and more effective assessment methods that are available to more patients and that enable physicians to judge how and when to initiate these improved therapies. n Willis and Gradl, 2010. 19 
